68P - Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of th...
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Anti-Cancer Agents & Biologic Therapy
Small-Cell Lung Cancer
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
G. Mountzios1, C. Emmanouilidis2, N. Vardakis2, E. Kontopodis2, D. Hatzidaki2, E. Popis2, N. Karachaliou2, A. Kotsakis2, M. Agelidou2, V. Georgoulias2
Therapeutic options for patients with relapsed, chemo-resistant small-cell lung cancer (SCLC) are limited. Since paclitaxel has demonstrated single-agent activity in the second-line setting of SCLC and angiogenesis seems to play an important role in the pathogenesis of the disease, a phase II trial was conducted in order to evaluate the efficacy and the tolerance of their combination in patients with relapsed, chemo-resistant SCLC.
Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 who experienced relapse within 3 months after completion of 1st line chemotherapy for SCLC were eligible. Patients were treated with paclitaxel (90 mg/m2, days 1, 8 and 15) along with bevacizumab (10 mg per kgr of body weight, days 1 and 15) in cycles of 28 days.
Thirty patients (male/female: 27/3) with a median age of 64 years and ECOG Performance Status 0/1/2: 2/25/3 were enrolled. Nineteen patients (63.3%) had received at least two lines of prior treatment, 17 (56.7%) had undergone prior radiotherapy and nine (30%) had brain metastases at the time of study entry. The overall objective response rate was 20% (95% CI: 5.69%-34.31%), including one complete remission, whereas the disease control rate was 36.7%. The median duration of response was 2.5 months (range, 1.5–5.7), the median progression-free survival 2.7 months (range, 0.5 – 9.2) and the median overall survival 6.3 months (range 0.5 – 17.9). Grade 3 and 4 toxicities were limited in neutropenia, diarrhea and fatigue. There was one case of non-fatal pulmonary embolism.
The combination of paclitaxel with bevacizumab was feasible and active in this poor prognosis and heavily pretreated population of patients with advanced, chemoresistant SCLC, representing a valid therapeutic alternative which merits further evaluation.
All authors have declared no conflicts of interest.